A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Capecitabine; Eribulin; Vinorelbine; Vinorelbine
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms ALPHABET
- 09 Apr 2024 Planned End Date changed from 1 Sep 2026 to 1 Nov 2024.
- 09 Apr 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Nov 2024.
- 09 Apr 2024 Status changed from recruiting to active, no longer recruiting.